KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
暂无分享,去创建一个
B. Monk | T. Fehm | N. Colombo | K. Hasegawa | R. Shapira-Frommer | S. Keefe | K. Tewari | C. Dubot | J. Alexandre | K. Stein | J. Li | M. V. Caceres